

# William B Wong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5293389/publications.pdf>

Version: 2024-02-01

33  
papers

639  
citations

687220

13  
h-index

610775

24  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1024  
citing authors

#	ARTICLE	IF	CITATIONS
1	Alignment of health plan coverage policies for somatic multigene panel testing with clinical guidelines in select solid tumors. <i>Personalized Medicine</i> , 2022, 19, 171-180.	0.8	4
2	Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2022, 40, 623-631.	1.7	3
3	A Pragmatic Guide to Assessing Real Option Value for Medical Technologies. <i>Value in Health</i> , 2022, 25, 1878-1884.	0.1	4
4	Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices. <i>Clinical Lung Cancer</i> , 2021, 22, e470-e480.	1.1	10
5	Novel Approach Using Administrative Claims to Evaluate Trends in Oncology Multigene Panel Testing for Patients Enrolled in Medicare Advantage Health Plans. <i>JCO Precision Oncology</i> , 2021, 5, 792-801.	1.5	2
6	Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing. <i>JCO Oncology Practice</i> , 2021, 17, e1774-e1784.	1.4	21
7	CTN-related peptide 8 (CTRP8) in human prostate cancer. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
8	Real-world evidence for option value in metastatic melanoma. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1-10.	0.5	1
9	Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1271-1282.	0.6	12
10	Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data. <i>Value in Health</i> , 2021, 24, 1746-1753.	0.1	5
11	Estimated Impact of Public and Private Sector COVID-19 Diagnostics and Treatments on US Healthcare Resource Utilization. <i>Advances in Therapy</i> , 2021, 38, 1212-1226.	1.3	6
12	Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in nonsmall cell lung cancer. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, , 1-10.	0.5	2
13	Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination. <i>JAMA Network Open</i> , 2021, 4, e2138219.	2.8	21
14	Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics. <i>Oncologist</i> , 2020, 25, e1743-e1752.	1.9	21
15	Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non-small-Cell Lung Cancer With Liver Metastases. <i>Journal of Oncology Practice</i> , 2019, 15, e878-e887.	2.5	8
16	Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, e948-e956.	2.5	14
17	The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors. <i>Journal of Medical Economics</i> , 2019, 22, 414-420.	1.0	10
18	Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 75-82.	1.0	7

#	ARTICLE	IF	CITATIONS
19	Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2018, 36, 495-504.	1.7	24
20	Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings. <i>Clinical Lung Cancer</i> , 2018, 19, 139-147.	1.1	15
21	ALK Testing Trends and Patterns Among Community Practices in the United States. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	27
22	Assessment of costs associated with adverse events in patients with cancer. <i>PLoS ONE</i> , 2018, 13, e0196007.	1.1	86
23	Oncologists'™ Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 565-571.	0.5	14
24	The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. <i>Journal of Medical Economics</i> , 2017, 20, 671-677.	1.0	28
25	P1.01-008 Real-World Patient Characteristics, Testing and Treatment Patterns of ALK+ NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1894-S1895.	0.5	1
26	Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 160.	1.0	14
27	Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma. <i>American Journal of Ophthalmology</i> , 2016, 168, 78-85.	1.7	10
28	Statins in the prevention of dementia and Alzheimer's disease: A meta-analysis of observational studies and an assessment of confounding. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 345-358.	0.9	96
29	An adherence based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%. <i>Current Medical Research and Opinion</i> , 2013, 29, 1191-1200.	0.9	3
30	Prioritization in Comparative Effectiveness Research. <i>Medical Care</i> , 2012, 50, 388-393.	1.1	21
31	The value of comparative effectiveness research: Projected return on investment of the RxPONDER trial (SWOG S1007). <i>Contemporary Clinical Trials</i> , 2012, 33, 1117-1123.	0.8	45
32	Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer. <i>Journal of Medical Economics</i> , 2011, 14, 159-166.	1.0	10
33	Cost Effectiveness of Pharmacogenomics. <i>Pharmacoeconomics</i> , 2010, 28, 1001-1013.	1.7	94